inhibitor

Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Commenting Expert: Emiel Rutgers, Netherlands Cancer Institute, Amsterdam Angel Rod

Egbert Smit EGBERT SMIT, Free University of Amsterdam There are a number of promising new molecular targets for lung cancer chemotherapy which were discussed at the Turin congress by Egbert Smit. He t

Silvia Novello SILVIA NOVELLO, University of Turin Future improvements in drug treatment of lung cancer may be made by inhibiting more than one tyrosine kinase simultaneously. So said Silvia Novello w

David Cunningham REFERENCE: Abstract 3012, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 DAVID CUNNINGHAM, Royal Marsden Hospital, London The oral agent capeticabine

Jack Cuzick JACK CUZICK, Wolfson Institute of Preventive Medicine, London New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continu

Anthony Fung REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida ANTHONY FUNG, University of British Columbia, Vanc

Georg Härter REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007 GEORG HÄRTER, University Hospital, Ulm For patients with multiple myeloma b

Pierre Laurent-Puig Bill Hait REFERENCE: ABSTRACT: 5671, American Association for Cancer Research, April 14-18, 2007, Los Angeles PIERRE LAURENT-PUIG, Hôpital Européen Georges Pompidou, Paris COMMEN

Paul Fisher REFERENCE: Meet the Professor Session, AACR 2007, Los Angeles PAUL FISHER, Columbia University, New York Patients with cancer could soon be treated with adenoviruses capable of infecting b

SUZANNE OPARIL, University of Alabama, Birmingham REFERENCE: Abstract 405-12, American College of Cardiolgy New Orleans A combination of two antihypertensive agents has given improved blood pressure c

ROY STEIGBIGEL, State University of New York at Stony Brook JOHN W. MELLORS, University of Pittsburgh REFERENCE: Abstract 105aLB, 105bLB, 14th Conference on Retroviruses and Opportunistic Infections,

Francis Giles Ken Kaushansky Heather Leitch Nancy Berliner Corrado Tarella Vincent Rajkumar Robert Kyle Aurora Kinase BCR-ABL Inhibitor Beats T315-I Mutation in Patients with Chronic Myeloid Leukemia

Joseph Muhlestein Sidney Smith Joost Daemen Drug Eluting Stents: More Deaths in Real World Use REFERENCE: American Heart Association Scientific Sessions, Chicago, November 12-15, 2006. Abstract: 2225

Theodore Mazzone Timothy Gardner Christopher Cannon Atherosclerosis Halted in Type 2 Diabetes by Pioglitazone for Glycemic Control REFERENCE: American Heart Association Scientific Sessions, Chicago, N

Arlene Forastiere Everett Vokes Michael Skinner Mark Chambers Larynx Cancer: Concurrent Chemoradiotherapy: Best for Larynx Preservation REFERENCE: Abstract 5517 Arlene Forastiere, Sidney Kimmel Compre

Timothy Wilkin Timothy Wilkin, Weill Cornell Medical College, New York A protease inhibitor, currently known as TMC114 has been tested in the POWER II study among some 300 patients who had failed mult

John McMurray The VALIANT trial compared ACE-inhibitor, ARB and a combination of the two in high-risk post-MI patients, and found there may be an interaction between them and statins. John McMurray fr

Registry analysis suggests women often receive too much treatment with glycoprotein 2B3A inhibitors. Duke University’s Karen Alexander told us more. [audio:https://www.audiomedica.com/podcasting

Gunnar Gislason As the dust continues to settle on the Vioxx issue, there is naturally a desire to look further at potential cardiovascular risks associated with COX-2 inhibitors and, indeed, other no

Audio Medica talked with Roberto Ferrari , Vice President of the ESC, about the PREAMI study on the use of the ACE inhibitor perindopril in older patients who have survived acute myocardial infarction

Ronnie Willenheimer It could be just as good to start treatment for heart failure with a beta blocker first and subsequently use an ACE inhibitor, as the more convetional use of an ACE inhibitor first